Development of a Breath Analyzer for Asthma Screening
Sponsor: American Lung Association
A observational or N/A phase clinical study on Asthma, this trial is ongoing. The trial is conducted by American Lung Association and has accumulated 6 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Study Description(click to expand)The study plan is divided into two sections: in-clinic studies and large-scale outreach screening. (A). Clinical Studies The clinical study is intended to obtain data characterizing eNO concentrations within individual groups of subjects listed in the inclusion criteria. The type of this study is "non-invasive", and the study design is "diagnosis/ treatment monitoring, and efficacy". The study will seek to recruit subjects who fall into one of the categories listed in the inclusion criteria below. The number of subjects (n) to be recruited for each category is given and is estimated based on the past number of subjects mainly at the Ekips Technologies, The Oklahoma Allergy \& Asthma Clinic, and the Norman Lung Center sites. Inclusion Criteria (Total Number of Subjects, n = 700) Both genders are eligible for this study: 1. Healthy subjects (n=120) 2. Asthma (Total n=450) \[diagnosed according to NHLBI/ NAEPP Guidelines (1998)\] 1. Non-treated or B2-agonist treated asthmatics (n=150), 2. Glucocorticoid treated asthmatics, (n=150), 3. Leukotriene Antagonist treated asthmatics, (n=75), 4. Glucocorticoid and Leukotriene Antagonists treated asthmatics, (n= 75). 3. Acute respiratory illnesses (n=65 a) Sinusitis (Acute and Chronic), b) Influenza, c) Common cold, d)Pneumonia, e)Related symptoms, but no diagnosis. 4. Allergies (n=65) a) Atopic dermatitis,...
The study plan is divided into two sections: in-clinic studies and large-scale outreach screening.
(A). Clinical Studies The clinical study is intended to obtain data characterizing eNO concentrations within individual groups of subjects listed in the inclusion criteria. The type of this study is "non-invasive", and the study design is "diagnosis/ treatment monitoring, and efficacy". The study will seek to recruit subjects who fall into one of the categories listed in the inclusion criteria below. The number of subjects (n) to be recruited for each category is given and is estimated based on the past number of subjects mainly at the Ekips Technologies, The Oklahoma Allergy \& Asthma Clinic, and the Norman Lung Center sites.
Inclusion Criteria (Total Number of Subjects, n = 700)
Both genders are eligible for this study:
1. Healthy subjects (n=120) 2. Asthma (Total n=450) \[diagnosed according to NHLBI/ NAEPP Guidelines (1998)\]
1. Non-treated or B2-agonist treated asthmatics (n=150), 2. Glucocorticoid treated asthmatics, (n=150), 3. Leukotriene Antagonist treated asthmatics, (n=75), 4. Glucocorticoid and Leukotriene Antagonists treated asthmatics, (n= 75). 3. Acute respiratory illnesses (n=65
a) Sinusitis (Acute and Chronic), b) Influenza, c) Common cold, d)Pneumonia, e)Related symptoms, but no diagnosis. 4. Allergies (n=65) a) Atopic dermatitis, b) Allergic rhinitis, c) Seasonal allergies.
Healthy Subjects Recruiting
Healthy subjects will be recruited from visitors and patients at the study sites. Visitors may include relatives or friends accompanying patients. Healthy employees at the study sites may be asked to participate in the study. Patients, visitors, and employees will be told that do not have to participate if they do not want to.
Exclusion Criteria
Subjects younger than 4 and older than 65 will be excluded from the study. Pregnant women will also be excluded from the study.
Duration of Participation
For each visit, the participant in the study will be asked to donate up to 3 breath samples for the first visit. The total time required for breath donations and measurements will be about 5 minutes. An additional five minutes of a subject's time are needed to complete a short interview if the information needed is not already available.
Asthmatic or suspected asthmatic patients, both treated and non-treated will be asked to donate breath during additional visits if convenient. Follow-up measurements may be performed during regularly scheduled office visits.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status
-
Apr 2018 — Jan 2021 [monthly]
Unknown Status
Phase: EARLY_PHASE1 → None
-
Feb 2017 — Apr 2018 [monthly]
Unknown Status EARLY_PHASE1
Phase: Phase 0 → EARLY_PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status Phase 0
First recorded
Sep 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- American Lung Association
- Ekips Technologies
For direct contact, visit the study record on ClinicalTrials.gov .